Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency

Efficacy and Safety of Ginkgo Biloba Standardized Extract (24% Ginkoflavonoglicozides and 6% Terpenes) in Treatment of Mild Cognitive and Concentration Impairment

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00446485

Enrollment

Registered

2007-03-13

Start date

2007-05-31

Completion date

2010-04-30

Last updated

2015-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular Insufficiency, Mild Cognitive Impairment

Keywords

ginkgo biloba, cerebrovascular insufficiency, mild cognitive impairment, concentration impairment

Brief summary

The purpose of the study is to determine weather Ginkgo biloba standardized extract (24% ginkoflavonoglicozides and 6% terpenes) is effective in treatment of cognitive and concentration impairment

Detailed description

Inclusion criteria is cerebrovascular insufficiency MNSE\>20. 90 patients are divided into three groups randomly. First group is being administered 120 mg ginkgo biloba extract, second group 60 mg of the extract and the third group has being administered placebo during the period of 6 months. Methods used for evaluation are SCAG, MMSE, MDRS, VFT, CGI, TCD and color Doppler of carotid arteries. Methods used for follow up safety include: routine blood tests, biochemical tests, neurologic and physical examination, vital signs and ECG.

Interventions

DRUGGinkgo biloba standardized extract 24/6

tablets, 120 mg/day (60 mg two times daily) during 6 months

DRUGGinkgo Biloba standardized extract 24/6

tablets, 60 mg/day during 6 months

DRUGplacebo

placebo during 6 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* cerebrovascular insufficiency and mild cognitive disorder (MMSE=20-28)

Exclusion criteria

* pregnancy * cognitive disorder caused by psychological, metabolic endocrine nutritional and heart disorder * alcohol or drug abuse

Design outcomes

Primary

Measure	Time frame
Changes of MMSE	6 months
Changes of MDRS	6 months
Changes of VFT	6 months
Changes of CGI	6 months
Changes of SCAG	6 months

Secondary

Measure	Time frame
Changes of platelets, hematocrit, prothrombin time, and activated partial tromboplastin time	6 months
Changes of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides	6 months
Safety will be assessed according to occurrence of adverse events during the trial	6 months
Changes of TCD, and color Doppler of carotid arteries	6 months

Countries

Croatia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026